Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Alumis Inc. Common StockNASDAQ: ALMS
Accumulated OCI · Q2 FY2026 · quarter ended Jun 2026
Accumulated OCI turns negative
Q2 FY2026 Accumulated OCI was -$683K, compared with $22K a year earlier.
Context
- Accumulated OCI amounted to 0.1% of total assets at the end of Q2 FY2026, up 0.1 pp from a year earlier.
- Accumulated OCI increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -3204.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 188K USD
- Year-over-year change
- +370.0%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 188K | +370.0% |
| FY2024 | 2024-12-31 | 40K | +1900.0% |
| FY2023 | 2023-12-31 | 2K | +101.6% |
| FY2022 | 2022-12-31 | (127K) | — |
Accumulated OCI vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -3204.5% is the 6th highest of 7, against a peer median of -97.5%.
- Accumulated OCI amounts to 0.1% of total assets for ALMS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | €56.72M EUR | +21.7% | +9.8% | 115.9% | |
| Dec 2025 | $9.68M USD | -91.7% | -56.2% | 84.2% | |
| Mar 2026 | $22K USD | -94.9% | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | -$6K USD | — | — | 0.0% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | -$18K USD | — | — | 0.0% |
| Mar 2026 | -$128K USD | -6300.0% | — | 0.0% | |
| Mar 2026 | -$146K USD | -190.7% | — | 0.0% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | -$683K USD | -3204.5% | — | 0.1% |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | -€966K EUR | — | — | 0.6% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -97.5% | -23.2% | 0.0% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.